Gamida Cell Ltd. (GMDA), which recently secured FDA approval for its cell therapy Omisirge, on Monday, said that it is seeing high interest from transplant centers, exceeding its expectations.
The U.S. Food and Drug Administration approved Gamida Cell Ltd.'s Omisirge (omidubicel-onlv) cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation.
The FDA approved Omisirge, an allogeneic cell therapy from Gamida Cell that could improve access to stem cell transplants as treatments for blood cancers. The biotech makes its therapy from umbilical cord blood.
Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant
Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and. | April 17, 2023
By Josh Beckerman Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S. Food and Drug Administration approved the Boston-based biotechnology company s Omisirge cell therapy for. | April 17, 2023